E-mail Address
[email protected]

Aaron Figg, Director
"We strive to support our customers in developing more and better biopharmaceuticals to treat patients. By continually innovating to create unique and unrivalled technologies, we bring practical solutions to the problems of the drug discovery and development process"

Optimising workflows

We provide solutions for customers working across cell line development:

Novel Biotherapeutics

Isolate, screen and characterise attributes for clones producing novel recombinant proteins e.g. monoclonal antibodies or therapeutic proteins for rare diseases

Read More >

Biosimilars and Biobetters

Generate stable cell lines to create equivalents (Biosimilars) or improved versions (Biobetters) of existing blockbuster therapeutic antibodies for which the patent has, or will shortly, expire

Read More >

Gene Therapy

Develop new, stable, producer cell lines manufacturing viruses to subsequently infect target cells of patients

Read More >

Gene Editing & Cell Engineering

Optimise your drug discovery process using targeted gene editing to create stable cell lines as cellular reagents, for use in target validation, functional genomics and disease modelling

Read More >


"How a Top-5 Pharma Doubled the Speed of Cell Line Development"

Latest News

Join Solentim in meeting Europe’s leading innovators at Biologics World Nordic

Nordic region comes out top in the annual European Innovation Scoreboard (EIS) which provides a comparative assessment of research and innovation performance across the EU Life

Solentim are Recruiting | R&D Director

Company Information: About Solentim Solentim is a Life Sciences company committed to transforming the discovery and development of new biologics, to get materials into the clinic faster and to drive

Insights and advances in CRISPR, cell line development and drug discovery

Solentim, a global leader in cell line development instrumentation, is pleased to announce it will be exhibiting at ELRIG’s second CRISPR in Drug Discoveryconference, 4-5 March 2020 at the Babraham

Customer case study in brief: Celonic AG

Enrichment by FACS combined with Solentim’s VIPS & Cell Metric cut CLD workflow timelines at a major European CDMO by nearly 50% and reduced plate numbers by up to 96%

Understanding the latest FDA guidance on investigational new drugs for cell and gene therapy

On the 28th January 2020 we saw the FDA update its guidance for industry regarding chemistry, manufacturing, and control (CMC) on the application of (INDs) for cell and gene therapy,

The A-Z of Cell Line Development

The Cell Line Development (CLD) space is growing and evolving quickly. Our understanding of technology is advancing at an unprecedented rate, with more equipment and tech reaching the market every